bexmarilimab + azacitidine + venetoclax

bexmarilimab + azacitidine + venetoclax is an investigational triple-drug combination for hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). - **Bexmarilimab** is a monoclonal antibody that targets Clever-1, an immunosuppressive macrophage receptor, reprogramming macrophages to a pro-inflammatory state, enhancing antigen presentation, and sensitizing leukemic cells to other treatments. - **Azacitidine** is a hypomethylating agent (pyrimidine nucleoside analog of cytidine) that induces DNA hypomethylation and cytotoxicity in abnormal hematopoietic cells. - **Venetoclax** is a small molecule inhibitor of B-cell lymphoma-2 (BCL-2), promoting apoptosis in malignant cells. Recent preclinical and early clinical data indicate that adding bexmarilimab to azacitidine and venetoclax can overcome resistance in AML and MDS, with the triple therapy demonstrating enhanced anti-leukemic activity, particularly in venetoclax-resistant samples. This regimen is under investigation in phase 1/2 studies in relapsed/refractory and frontline higher-risk cases[1][2][3].